

Lawrence Berkeley National Laboratory

LBL Publications

Title

Development of Half-Sandwich Ru, Os, Rh, and Ir Complexes Bearing the Pyridine-2-ylmethanimine Bidentate Ligand Derived from 7-Chloroquinazolin-4(3H)-one with Enhanced Antiproliferative Activity.

Permalink

<https://escholarship.org/uc/item/1918d49x>

Journal

ACS Omega, 9(16)

Authors

Łomzik, Michał
Błauz, Andrzej
Tchoń, Daniel
[et al.](#)

Publication Date

2024-04-23

DOI

10.1021/acsomega.3c10482

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Development of Half-Sandwich Ru, Os, Rh, and Ir Complexes Bearing the Pyridine-2-ylmethanimine Bidentate Ligand Derived from 7-Chloroquinazolin-4(3H)-one with Enhanced Antiproliferative Activity

Michał Łomzik,* Andrzej Błaż, Daniel Tchoń, Anna Makal, Błażej Rychlik, and Damian Plazuk*



Cite This: *ACS Omega* 2024, 9, 18224–18237



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Kinesin spindle protein (KSP) inhibitors are one of the most promising anticancer agents developed in recent years. Herein, we report the synthesis of ispinesib-core pyridine derivative conjugates, which are potent KSP inhibitors, with half-sandwich complexes of ruthenium, osmium, rhodium, and iridium. Conjugation of 7-chloroquinazolin-4(3H)-one with the pyridine-2-ylmethanimine group and the organometallic moiety resulted in up to a 36-fold increased cytotoxicity with IC_{50} values in the micromolar and nanomolar range also toward drug-resistant cells. All studied conjugates increased the percentage of cells in the G_2/M phase, simultaneously decreasing the number of cells in the G_1/G_0 phase, suggesting mitotic arrest. Additionally, ruthenium derivatives were able to generate reactive oxygen species (ROS); however, no significant influence of the organometallic moiety on KSP inhibition was observed, which suggests that conjugation of a KSP inhibitor with the organometallic moiety modulates its mechanism of action.



INTRODUCTION

Despite the recent development of many cancer treatments, chemotherapy remains the primary, and often the only, method used.^{1–3} Among the numerous anticancer drugs, antimetabolic compounds such as taxanes and *Vinca* alkaloids are the most important.^{2,4} Antimetabolic agents such as taxanes disrupt the typical microtubule dynamics, leading to cancer cell death but can also cause many side effects, such as bleeding, immune system impairment, reduced blood pressure, and pain in muscles and joints.^{5–7} Additionally, the multidrug resistance phenomenon can be observed during chemotherapy, thus decreasing its efficiency. Therefore, developing new molecules able to overcome the drawbacks of currently used antimetabolic compounds is still essential.

In the last years, low-molecular-weight inhibitors of the kinesin spindle protein (KSP) were developed.⁵ The KSP is a member of the motor protein family and plays a crucial role in spindle pole separation. It is highly active in dividing cells, while its activity is almost undetectable in nondividing cells.⁸ KSP inhibitors disturb the mitosis without direct microtubule disruption.^{8–10} Numerous KSP inhibitors have been developed, including monastrol,¹¹ dimethylenastron,⁸ ispinesib (SB-715992), SB-743921,^{8,12} litronesib (LY2523355),¹³ MK-0731,¹⁴ and filanesib (ARRY-520).^{15,16} Some of these compounds have been clinically tested in at least 45 phase I/

II trials against various types of cancer,¹³ with ispinesib^{12,17} and filanesib^{15,18,19} as the most promising candidates. Encouraging results of clinical trials of ispinesib use in patients with metastatic or relapsing squamous cell carcinoma of the head and neck, with no signs of disease progression or intolerable toxicity, were observed within 21 days of the first dose;²⁰ however, up to date, no further phase III studies have been reported.


One of the fruitful methods to develop new anticancer drug candidates involves constructing conjugates of active compounds with an organometallic group.^{21–23} The most intensively studied organometallic derivatives include metallocenes²⁴ (mainly ferrocene and ruthenocene) and half-sandwich complexes of ruthenium,^{25–28} osmium,^{26,29} rhodium,³⁰ and iridium.³⁰ Organometallic compounds have several advantages over purely organic molecules. The presence of an organometallic moiety can increase the affinity to the biological targets by allowing the formation of new hydrophobic or

Received: December 29, 2023

Revised: March 28, 2024

Accepted: April 2, 2024

Published: April 13, 2024






Figure 1. Structure of (a) ispinesib, (b) its quinazoline-derived Ru, Os, Rh, and Ir half-sandwich conjugates reported previously,^{44,45} and (c) compounds studied herein.

Scheme 1. Synthesis of Complexes 3a–4d





Figure 2. Overlapped ¹H DOSY spectra of **3a** (blue) and (R)-1 (red) in DMSO-*d*₆.

metal–organic interactions with the protein. Organometallic compounds often have access to a protein binding site that is inaccessible to organic molecules. In addition, the presence of a metal atom often increases the ability of the compound to

generate reactive oxygen species (ROS), which can induce apoptosis. Organometallic conjugates often exhibit stronger antiproliferative properties than parent compounds and, in many cases, exhibit additional biological properties. In recent

years, many new organometallic conjugates of antimetabolic compounds have been developed, including derivatives of curcumin,^{31,32} taxanes,^{33,34} colchicine,^{35–37} ethacrynic acid,^{38,39} paullone,⁴⁰ or podophyllotoxin.^{41,42} The resulting conjugates demonstrate a higher antiproliferative activity or a new mechanism of action, being highly selective against tumor cells.

Recently, we have reported the synthesis and biological evaluation of a series of ferrocenyl⁴³ and Ru, Os, Rh, and Ir half-sandwich^{44,45} conjugates of ispinesib and its 7-chloroquinazolin-4(3H)-one core. Continuing our study on novel organometallic antimetabolic agents, we designed new half-sandwich complexes derived from the ispinesib core. Herein, we present the synthesis, structure, and biological activity studies of novel Ru, Os, Rh, and Ir half-sandwich complexes bearing the pyridine-2-ylmethanimine bidentate ligand derived from 7-chloroquinazolin-4(3H)-one (Figure 1).

RESULTS AND DISCUSSION

Synthesis. The half-sandwich complexes **3a–d** and **4a–d** were synthesized in two steps according to Scheme 1. First, (*R*)- and (*S*)-**2** imine ligands were generated in situ by reacting (*R*)- and (*S*)-**1** with 2 equiv of pyridine-2-carbaldehyde in anhydrous ethanol for 1 h. Next, 0.5 equiv of the proper dimetallic precursor $[(\text{cym})\text{MCl}_2]_2$ ($\text{M} = \text{Ru}$ for **3a** and **4a**, $\text{M} = \text{Os}$ for **3b** and **4b**) or $[(\text{Cp}^*)\text{MCl}_2]_2$ ($\text{M} = \text{Rh}$ for **3c** and **4c** or $\text{M} = \text{Ir}$ for **3d** and **4d**) was added to the reaction mixture. After 3 h of stirring at RT, the desired complexes **3a–d** or **4a–d** were isolated as hexafluorophosphate salts in 37–73% yield. All complexes were fully characterized by ¹H and ¹³C{¹H} NMR spectroscopy and ESI-MS analyses. The purity of compounds was confirmed by elemental analysis.

It might be expected that a mixture of diastereoisomers of **3a–d** and **4a–d** would be formed as the result of the complexation reactions of enantiomerically pure imines **2** due to the generation of new chirality on the metal atoms. In the ¹H NMR spectra of **3a–c** and **4a–c**, only one main set of peaks was observed in ¹H and ¹³C{¹H} NMR spectra together with small amounts (~15%) of a second species, which can be assigned to the other diastereoisomers. Yet, for iridium complexes (**3d** and **4d**), we detected much more intensive signals originating from the second diastereoisomer (ratio of 1:0.4 for **3d** and ratio of 1:1 for **4d**). The formation of two diastereoisomers of the complexes was also confirmed by diffusion-ordered spectroscopy (DOSY) experiments (Figures 2 and S1–S3). For example, the DOSY spectra of **3a** and (*R*)-**1** (Figure 2) confirmed that all ¹H signals observed in the ¹H NMR spectra originate from the molecule(s) showing the same diffusion coefficient.

Notwithstanding, the DOSY experiments confirmed the presence in the solution of compounds showing the same diffusion coefficient. The formation of diastereoisomers of complexes **3a–4d** was confirmed by HPLC-MS analysis (Figures S9–S16). For example, the HPLC-MS analysis of both ruthenium complexes reveals two peaks at $\tau_1 = 3.50$ and $\tau_2 = 5.22$ min for **3a**, with a ratio of 1:5, with the m/z of 701 assigned to $[\text{M}_{3\text{a-PF}_6}]^+$, and $\tau_1 = 3.39$ and $\tau_2 = 5.07$ min for **4a**, with a ratio of 1:4.3, with the m/z of 701 assigned to $[\text{M}_{4\text{a-PF}_6}]^+$. Likewise, the HPLC-MS analysis of both osmium complexes **3b** and **4b** confirmed the formation of two diastereoisomers with the ratio of 1:4 (Figures S11 and S12). In the case of iridium complexes (**3d** and **4d**), the ratio of HPLC peaks is 1:0.4 for **3d** and 1:1.4 for **4d**, corresponding

with the results observed in ¹H NMR. However, for rhodium complexes (**3c** and **4c**), only the main peak at $\tau_1 = 2.67$ min for **3c** and $\tau_1 = 2.79$ min for **4c**, with an additional small peak (ratio 1:0.08), and small peaks at $\tau_2 = 2.26$ min for **3c** and $\tau_2 = 2.40$ min for **4c** with the m/z of 334 assigned to $[\text{M}_{3\text{c-Cl-PF}_6}]^{2+}$ and $[\text{M}_{4\text{c-Cl-PF}_6}]^{2+}$ were detected.

On the ¹H NMR spectra of complexes **3a–b** and **4a–b** at 300 K, aromatic *p*-cymene proton signals were broad singlets. Also, no correlation between aromatic *p*-cymene protons or proton–carbon correlations in ¹H–¹H COSY or ¹H–¹³C HSQC NMR spectra was observed. Therefore, we performed VT-NMR experiments for **3a** and **3b** in DMSO-*d*₆ at various temperatures between 300 and 330 K (Figures 3 and S4a–d).




Figure 3. VT-NMR experiments for **3a**. ¹H NMR spectra in DMSO-*d*₆ (range 6.45–5.35 ppm) at (a) 300, (b) 310, (c) 320, and (d) 330 K; * denotes the signals assigned to the solvated compound.

An increase in the temperature of the sample from 300 to 330 K results in a change of broad singlets at 6.18 and 6.00 ppm into actual doublets and a doublet at 5.87 ppm, which were assigned to aromatic *p*-cymene protons. Additionally, a small set of signals, most likely originating from the hydrolyzed form of the complex, was observed during the experiment. The ¹H–¹H COSY and ¹H–¹³C HSQC spectra allowed observing the expected correlations between aromatic *p*-cymene protons and carbon atoms (Figures S5 and S6) at 330 K. However, those experiments confirmed the partial thermal decomposition of studied complexes, which impeded the performed ¹³C{¹H} NMR spectra. Identical results were observed for **4a** and **4b** (300 and 330 K) (Figures S7, S8, S45–S47, S59–S61).

It could be expected that ligand **1** may undergo complexation forming the expected Type I complexes together with two other Type II and Type III complexes (Figure 4). The formation of Type III complexes was excluded by MS analysis. In the MS spectra of **3a–4d**, we observed only expected m/z values assigned to monocations $[\text{M}]^+$ (Figures S9–S16). To further exclude the formation of Type II complexes, we generated imine **5** in the reaction of **1** with benzaldehyde (Scheme 2). The obtained imine **5** further reacted with 0.49 equiv of metal dimers $[\text{LMCl}_2]_2$ ($\text{M} = \text{Rh}/\text{Ir}$, $\text{L} = \text{Cp}^*$ or $\text{M} = \text{Ru}/\text{Os}$, $\text{L} = \text{cym}$) in methanol at RT for 3 h. After the workup, we isolated only previously reported complexes **6a–d** bearing **1** as *N,N*-bidentate ligands in trace yield. As the formation of imines is reversible, unless coordinated to a metal,⁴⁶ imine **5** hydrolyzed in the presence of a trace of water to amine **1**, which underwent complexation with $[\text{LMCl}_2]_2$ to afford complexes **6a–d**. The NMR spectra of the isolated complexes were identical to those reported previously.⁴⁴




Figure 4. Three possible coordinations of the metal to ligand 2. Bidentate coordination of (a) Type I and (b) Type II and (c) tridentate coordination of Type III.

Scheme 2. Competitive Complexation of (S)-1 and 5 with [LMCl₂]₂





Figure 5. Oak Ridge thermal ellipsoid plot (ORTEP) representation of the molecular structure of **4a**^{S,S_{Ru}}: (a) molecule **4a**^{S,S_{Ru}} with the counterion, (b) molecule **4a**^{S,S_{Ru}} with the counterion, and (c) schematic representation of the ruthenium coordination sphere. Interatomic distances and angles reported in Table 1 are highlighted in blue. Atomic displacement parameters are drawn at the 50% probability level. Hydrogen atoms are represented as fixed-size spheres in panels (a) and (b) and omitted in panel (c). The cocrystallized disordered solvent molecule has also been removed for clarity.

X-ray Diffraction Studies. Although we obtained complexes as a mixture of two possible diastereoisomers, the

crystallization of **4a** from the dichloromethane/*n*-pentane mixture by slow evaporation in $-20\text{ }^\circ\text{C}$ allowed to isolate

only one enantiopure isomer $4a^{S,S_{Ru}}$. The complex $4a^{S,S_{Ru}}$ crystallized in the $P2_1$ space group and its chiral purity has been confirmed by a low value of the Flack parameter (Table S1).

The imine (*S*)-**2** acts as a *N,N*-bidentate ligand, forming five-membered rings with the metal ions by coordinating through the iminium and pyridinium nitrogen (Figure S5). Two similar structures of the complex are present in the unit cell, showing almost identical ruthenium coordination, varying slightly in the conformation of the terminal phenyl and ^tPr moieties. In Table 1, we had listed bond lengths of the coordination bonds for

Table 1. Selected Coordination Bond Lengths (Å) and Angles (deg) Found in Both Independent Molecules of $4a^{S,S_{Ru}}$ in Its Crystal Structure

bond or angle	$4a^{S,S_{Ru}}$	$4a^{S,S_{Ru}}$
Ru–Cl	2.396(1) Å	2.383(2) Å
Ru–N _{py}	2.082(4) Å	2.096(4) Å
Ru–N _{im}	2.131(4) Å	2.119(4) Å
Ru–μ [center of the <i>p</i> -cymene ring]	1.699(2) Å	1.695(2) Å
N _{im} –Ru–N _{py}	76.7(2)°	76.7(2)°
N _{im} –Ru–Cl	86.4(1)°	85.2(1)°
N _{py} –Ru–Cl	85.9(1)°	82.4(1)°
N _{im} –Ru–μ	135.55°	134.16°
N _{py} –Ru–μ	128.88°	132.27°
Cl–Ru–μ	127.11°	125.53°

both forms, which are typical for such types of complexes.^{47,48} A more thorough description of the molecular geometry has been presented in the ESI.

Stability Study. For biological studies, compounds are commonly administered as dimethyl sulfoxide (DMSO) solution to cells cultured in a specific medium such as Dulbecco's modified Eagle's medium (DMEM). DMEM consists of numerous organic compounds which may act as ligands for organometallics. Therefore, it is important to know how the compounds behave in such conditions. The two most prominent components of DMEM which may coordinate to half-sandwich complexes are *L*-cysteine and *L*-histidine. Both of those amino acids are present in DMEM at 0.2 mM concentration, so we studied how the complexes interact with them using UV–vis spectroscopy and HPLC-MS analysis. The DMSO solutions of complexes were added to the aqueous solution of *L*-cysteine or *L*-histidine to achieve a complex concentration of 20 μM while keeping the DMSO concentration at 0.5 vol %. The UV–vis spectra and HPLC-MS analysis indicate that neither ruthenium **3a** nor the osmium complex **3b** reacts with those amino acids within 2 h (Figures S18–S21, S24 and S25). The rhodium complex **3c** slowly reacts with *L*-cysteine (Figure S22) by increasing the intensity of each absorbance maximum ($\lambda = 279, 304, 317, 348$ nm). HPLC-MS analysis confirmed the formation of an additional peak at $\tau = 0.95$ min with m/z 714 assigned to $[M-Cl-PF_6 + HCOOH]^+$; additionally, the intensity of peaks corresponding to **3c** is lower (Figure S26). A similar effect is observed in the case of *L*-histidine, with an increase of only one maximum at $\lambda = 278$ nm, while the others are almost unchanged (Figure S23). On the other hand, the iridium complex **3d** reacts with both *L*-cysteine and *L*-histidine (Figure 6) in 40 min. The intensity of absorbance peaks at $\lambda = 287$ and $\lambda = 372$ nm in the presence of cysteine is decreasing, while the intensity of peaks at $\lambda = 304$ and $\lambda = 318$ nm is almost intact. HPLC-MS analysis

shows that the intensity of both peaks corresponding to **3d** is lower, while the additional peak at $\tau = 1.09$ min with m/z 804 is assigned to $[M-Cl-PF_6 + HCOOH]^+$ for the *L*-histidine experiment and at $\tau = 1.07$ min with m/z 804 is assigned to $[M-Cl-PF_6 + HCOOH]^+$ for the *L*-cysteine experiment (Figure S27). The lack of an isobestic point on the UV–vis spectra and HPLC-MS analysis indicate that the reaction does not lead to the dissociation of ligands **2** and is purely associated with Cl ligand exchange.

Biological Activity. Antiproliferative Potential. To assess the impact of conjugating half-sandwich complexes with amines **1** via an imine-pyridine ligand on biological activity, we examined the antiproliferative potential of (*R*)- and (*S*)-**1** and organometallic conjugates **3a–d** and **4a–d** in selected human cancer cell lines: alveolar basal epithelial cell adenocarcinoma (A549), colorectal adenocarcinomas (Colo205 and SW620), colorectal carcinoma (HCT116), hepatocellular carcinoma (HepG2), and breast adenocarcinoma (MCF7). The choice of cell lines was dictated by results of previously published clinical trials on ispinesib.^{49,50} All complexes demonstrate an antiproliferative potential in the micromolar or nanomolar range (Table 2, Figures S28 and S30). The activity of these compounds varies significantly depending on the configuration of imine-ligand **2** and the cell line tested. Complexation of the imine derived from (*R*)-**1** by osmium, resulting in complex **3b**, leads to an enhanced cytotoxicity toward A549 (2-fold), HepG2 (3-fold), and MCF7 (3-fold). A similar effect is observed for Rh **3c** and Ir **3d** complexes derived from imine (*R*)-**2**, characterized by a 2-fold increased antiproliferative potential toward A549. However, the complexation of imine (*R*)-**2** with ruthenium **3a** does not enhance the activity toward studied cell lines. Nevertheless, the complexation of the imine derived from (*S*)-**1** with all metals results in a significantly increased antiproliferative potential. It is especially evident in the case of the ruthenium complex **4a** (approximately 6-fold increased activity against MCF7 and Colo205), the osmium complex **4b** (increased cytotoxicity against Colo205 (7-fold), HCT116 (10-fold), and MCF7 (9-fold)), and the iridium complex **4d** (enhanced activity toward all tested cell lines, ranging from 9- to 36-fold). Notably, the iridium complex **4d** also exhibits a significantly higher cytotoxicity compared to both (*S*)-**1** and the more cytotoxic amine (*R*)-**1** (2.6- and 1.6-fold, respectively). Additionally, within the tested concentration ranges, all of the compounds studied show no antiproliferative effects on the normal MRC-5 cell line, with IC₅₀ values exceeding 100 μM (Figure S31).

Next, we evaluated the cytotoxicity of the synthesized complexes toward the panel of six multidrug-resistant (MDR) cell lines derived from SW620 and characterized by the overexpression of various ABC proteins, namely, ABCG2 (SW620C and SW620Mito), ABCC1 (SW620M and SW620E), and ABCB1 (SW620D, SW620E, and SW620V) (Table 3, Figures S29 and S32). Among the series of complexes bearing the (*R*)-**2** ligand, only the iridium complex **3d** shows a 2.2- and 1.7-fold higher cytotoxicity than the corresponding amine (*R*)-**1** toward SW620C and SW620D cancer cell lines. The activity of the complexes derived from the ligand (*S*)-**2** is also considerably higher than that of the compounds containing the ligand (*R*)-**2**. The cytotoxicity of both rhodium **4c** and iridium **4d** complexes is higher than that of amine (*S*)-**1**. In the case of **4c**, the increase in cytotoxicity is low, with the highest value of 3.7-fold for the SW620Mito line.




Figure 6. UV-vis spectra of **3d** in DMSO-water solutions in the presence of 0.2 mM (a) L-cysteine or (c) L-histidine. The absorbance maxima value changes vs time in the presence of (b) L-cysteine and (d) L-histidine.

Nevertheless, the IC_{50} values for the iridium complex **4d** are 6.1- to 20.6-fold lower than those for amine (*S*)-**1**. Compound **4d** also exerts a 2.1- and 2.6-fold higher cytotoxicity than (*R*)-**1** against the SW620C and SW620D lines.

Cell Cycle. Ispinesib leads to the formation of monopolar mitotic spindles and a blockade of chromosome segregation in cancer cells. Using flow cytometry, we assessed the cell cycle distribution in the SW620 and SW620E cells exposed to the studied compounds for 24 and 48 h. Only two complexes, rhodium **3c** and iridium **3d**, exhibit a significantly different impact on cell cycle phase distribution. In contrast, all other complexes demonstrate a pattern similar to the corresponding amines (*R*)- and (*S*)-**1**, as shown in Figure 7 and Table S2. Both complexes, **3c** and **3d**, decrease the percentage of cells in the G_1/G_0 phase and increase the percentage in the S and G_2/M phases. All other compounds exhibit a similar impact on cell phase distribution. Furthermore, prolonged exposure to the compounds increases the percentage of cells in the G_2/M phase, with the most intensive effect observed for **3c** and **3d**. These results suggest an aggravated mitotic arrest in cells treated with the rhodium **3c** and iridium **3d** complexes.

However, none of the studied compounds affects the cell cycle in SW620E cells, as demonstrated in Figure S33.

KSP Inhibitory Activity. The mechanism of the anticancer activity of ispinesib is related to the inhibition of the activity of the KSP. Thus, we studied the synthesized compounds' ability to inhibit KSP activity using the adenosine 5'-triphosphate (ATP) hydrolysis assay. The inhibitory ability of the KSP is strongly correlated with the configuration of the organic ligand and the type of metal coordinated. Only the derivatives bearing an organic ligand configuration (*R*) exhibit KSP inhibitory activity. In contrast, all compounds bearing an organic ligand in the (*S*) configuration demonstrate no inhibitory activity toward the KSP at a concentration of 100, 300, and 1000 nM (Figure 8). The reference compound, ispinesib, shows a high KSP inhibitory activity (KSP residual activity 2.2%) at 100 nM concentration, while amine (*R*)-**1** decreases the KSP activity to about 35%. While the complexation of ruthenium leads to the nonactive complex **3a**, the other metal complexes **3b-d** are able to inhibit KSP activity with the most active rhodium **3c** (47.5%), followed by iridium **3d** (64.0%) and osmium **3b** (71.8%) complexes. Interestingly, the most cytotoxic iridium complexes **3d** and **4d** are practically deprived of KSP inhibitory

Table 2. Antiproliferative Activity of (R)-1 and (S)-1 and Organometallic Complexes 3a–4d in Human Cancer Cell Lines^a

compound	IC ₅₀ [μ M]					
	A549	Colo205	HCT116	HepG2	MCF7	SW620
(R)-1	2.21 [1.88–2.59]	0.107 [0.094–0.121]	0.346 [0.274–0.437]	0.566 [0.476–0.672]	0.231 [0.195–0.308]	0.096 [0.080–0.117]
3a	2.45 [2.05–2.93] (0.902)	1.26 [1.16–1.38] (0.085)	2.88 [2.48–3.43] (0.120)	1.57 [1.45–1.70] (0.360)	0.858 [0.742–0.988] (0.269)	1.22 [1.12–1.33] (0.079)
3b	1.04 [0.983–1.07] (2.12)	0.448 [0.412–0.492] (0.239)	0.424 [0.388–0.476] (0.816)	0.188 [0.174–0.204] (3.01)	0.073 [0.068–0.079] (3.16)	0.556 [0.514–0.601] (0.173)
3c	1.16 [0.906–1.50] (1.90)	0.138 [0.125–0.153] (0.775)	0.173 [0.145–0.206] (2.00)	0.689 [0.605–0.784] (0.821)	0.357 [0.279–0.459] (0.647)	0.152 [0.125–0.185] (0.632)
3d	1.13 [0.973–1.32] (1.96)	0.524 [0.453–0.606] (0.204)	0.476 [0.408–0.550] (0.727)	0.454 [0.383–0.539] (1.25)	0.653 [0.552–0.767] (0.354)	0.198 [0.172–0.226] (0.485)
(S)-1	7.05 [6.42–7.36]	6.07 [5.18–7.39]	8.06 [7.29–8.90]	2.40 [2.18–2.63]	3.91 [3.56–4.31]	2.87 [2.68–3.06]
4a	3.25 [2.84–3.73] (2.17)	0.939 [0.737–1.20] (6.46)	3.76 [3.32–4.27] (2.14)	1.89 [1.64–2.17] (1.27)	0.634 [0.539–0.743] (6.17)	2.91 [2.63–3.21] (0.986)
4b	2.19 [2.00–2.40] (3.22)	0.904 [0.825–0.985] (6.71)	0.823 [0.658–1.07] (9.79)	1.13 [1.04–1.23] (2.12)	0.438 [0.398–0.483] (8.93)	2.31 [2.18–2.45] (1.24)
4c	3.79 [3.45–4.16] (1.86)	2.89 [2.64–3.15] (2.10)	2.94 [2.75–3.14] (2.74)	1.15 [0.833–1.58] (2.09)	1.50 [1.14–1.94] (2.61)	2.24 [1.95–2.61] (1.28)
4d	0.764 [0.613–0.954] (9.23)	0.216 [0.197–0.235] (28.1)	0.222 [0.192–0.254] (36.31)	0.218 [0.193–0.244] (11.01)	0.216 [0.191–0.244] (18.10)	0.139 [0.128–0.150] (20.65)

^aExposure time 72 h; IC₅₀ values are presented together with the corresponding 95% confidence intervals (in brackets), $n = 3$; the activity factors were calculated as IC₅₀₍₁₎/IC_{50(3a–4d)} and are given in parentheses below the confidence intervals.

activity. These results suggest the existence of another mechanism of anticancer activity than the ability to inhibit KSP activity.

ROS Generation. Metal complexes often induce reactive oxygen species (ROS) generation in cells,⁵¹ which may increase their cytotoxic activity compared to purely organic molecules. To study the impact of the synthesized compounds on ROS production, we have measured the ROS generation in SW620 cells by the dihydrorhodamine 123 (DHR123) oxidation assay (Figure 9). However, there is no correlation between the antiproliferative potential and the ability of a compound to generate ROS. Only Ru derivatives (3a and 4a) increase the level of ROS compared to the control or (R)- and (S)-1, and the level of the ROS generated by those complexes is virtually the same. In contrast, the other derivatives do not induce ROS generation.

CONCLUSIONS

We designed and synthesized a series of organometallic half-sandwich Ru, Os, Rh, and Ir complexes bearing the pyridine-2-ylmethanimine bidentate ligand derived from 7-chloroquinazolin-4(3H)-one. We obtained compounds that exhibited nanomolar IC₅₀ values, strongly dependent on the metal center, ligand configuration, and cell type. All studied molecules, with the most potent rhodium and iridium complexes derived from (R)-amine, force the cell cycle arrest in the G₂/M phase. Only rhodium and iridium complexes derived from (R)-imine possess KSP inhibitory activity,

however, to a lower extent than the corresponding amine. In contrast, all other complexes were significantly less or even nonactive. The complexation of imines derived from 1 only for Ru led to compounds able to do ROS generation. However, there is no clear correlation between the cytotoxicity, KSP inhibitory activity, impact on the cell cycle, and ROS generation ability. The results suggest that the complexation of the imines derived from amines (R)- and especially (S)-1 led to compounds showing different mechanisms of activity than the organic ligands. Further studies are planned to determine the mechanism of biological activity of the synthesized compounds.


EXPERIMENTAL SECTION

Materials and Methods. All of the reactions were carried out under an argon atmosphere. All commercially available chemicals and solvents were of analytical grade and used without further purification. OsO₄, RhCl₃·xH₂O, and IrCl₃·xH₂O were purchased from Precious Metals Online and Sigma-Aldrich. Bis[dichlorido(η^6 -*p*-cymene)ruthenium(II)] was purchased from Sigma-Aldrich. Bis[dichlorido(η^6 -*p*-cymene)osmium(II)],⁵² bis[dichlorido(η^5 -pentamethylcyclopentadienyl)rhodium(III)], and bis[dichlorido(η^5 -pentamethylcyclopentadienyl)iridium(III)]⁵³ were synthesized as described previously. (R)-1 and (S)-1 were synthesized according to a reported procedure.⁵⁴ ¹H and ¹³C{¹H} and ¹H–¹³C HSQC NMR spectra were recorded at 294 K on a Bruker Avance III 600 MHz spectrometer at 600.3

Table 3. Antiproliferative Activity of (R)-1 and (S)-1 and Organometallic Complexes 3a–4d in Multidrug-Resistant (MDR) Cancer Cell Lines^a

comp.	IC ₅₀ [μ M]						
	SW620	SW620C	SW620D	SW620E	SW620M	SW620V	SW620Mito
(R)-1	0.096	0.721	1.12	0.835	0.241	0.206	0.261
	[0.080–0.117]	[0.552–0.942]	[0.851–1.47]	[0.627–1.11]	[0.191–0.305]	[0.160–0.267]	[0.207–0.329]
3a	1.22	4.38	7.23	5.52	3.45	4.71	4.33
	[1.12–1.33]	[3.80–5.07]	[6.24–8.37]	[4.74–6.43]	[2.99–3.97]	[4.08–5.44]	[3.80–4.95]
	(0.079)	(0.165)	(0.155)	(0.151)	(0.070)	(0.044)	(0.060)
3b	0.556	1.17	3.92	3.52	0.591	1.03	0.748
	[0.514–0.601]	[1.08–1.27]	[3.60–4.27]	[3.25–3.83]	[0.522–0.667]	[0.953–1.12]	[0.683–0.815]
	(0.173)	(0.616)	(0.286)	(0.237)	(0.408)	(0.200)	(0.349)
3c	0.152	0.592	4.18	0.880	1.18	0.210	0.524
	[0.125–0.185]	[0.526–0.666]	[3.13–5.96]	[0.657–1.18]	[0.998–1.42]	[0.175–0.253]	[0.418–0.657]
	(0.632)	(1.22)	(0.268)	(0.949)	(0.204)	(0.981)	(0.498)
3d	0.198	0.335	0.644	1.02	0.247	0.267	0.268
	[0.172–0.226]	[0.297–0.377]	[0.565–0.732]	[0.928–1.13]	[0.222–0.275]	[0.224–0.317]	[0.233–0.311]
	(0.485)	(2.15)	(1.74)	(0.819)	(0.976)	(0.771)	(0.974)
(S)-1	2.87	3.33	4.15	4.05	3.46	3.44	3.91
	[2.68–3.06]	[2.94–3.78]	[3.65–4.75]	[3.57–4.61]	[3.03–3.98]	[3.00–3.94]	[3.46–4.44]
4a	2.91	4.36	6.01	5.46	3.24	5.01	3.68
	[2.63–3.21]	[3.90–4.88]	[5.24–6.88]	[4.77–6.26]	[2.91–3.61]	[4.43–5.58]	[3.29–4.10]
	(0.986)	(0.764)	(0.690)	(0.741)	(1.07)	(0.687)	(1.06)
4b	2.31	4.54	13.5	12.8	2.45	9.30	3.78
	[2.18–2.45]	[4.15–4.99]	[12.3–15.0]	[11.7–14.2]	[2.25–2.66]	[8.52–10.1]	[3.48–4.11]
	(1.24)	(0.738)	(0.307)	(0.316)	(1.41)	(0.370)	(1.03)
4c	2.24	2.97	6.07	6.20	2.25	2.98	1.05
	[1.95–2.61]	[2.55–3.45]	[4.88–7.85]	[4.96–8.05]	[1.95–2.59]	[2.58–3.45]	[0.878–1.25]
	(1.28)	(1.12)	(0.684)	(0.653)	(1.54)	(1.15)	(3.72)
4d	0.139	0.343	0.425	0.663	0.387	0.411	0.365
	[0.128–0.150]	[0.310–0.379]	[0.384–0.472]	[0.582–0.754]	[0.339–0.443]	[0.374–0.451]	[0.313–0.428]
	(20.65)	(9.71)	(9.76)	(6.11)	(8.94)	(8.37)	(10.71)

^aExposure time 72 h; IC₅₀ values are presented together with the corresponding 95% confidence intervals (in brackets), $n = 3$; the activity factors were calculated as IC₅₀₍₁₎/IC_{50(3a–4d)} and are given in parentheses below the confidence intervals.

**Figure 7.** Cell cycle distribution in SW620 cells: (a) after 24 h and (b) after 48 h.

MHz for ¹H and at 150.1 MHz for ¹³C{¹H}. The ¹H and ¹³C{¹H} chemical shifts were calibrated based on the residual ¹H and ¹³C{¹H} solvent peaks, i.e., $\delta = 3.58$ ppm for ¹H and 67.2 ppm for ¹³C in THF-*d*₈, $\delta = 2.50$ ppm for ¹H and 39.5 ppm for ¹³C in dms-*d*₆ and $\delta = 5.32$ ppm for ¹H and 53.8 ppm for ¹³C in CD₂Cl₂. The UV–vis spectra were recorded at 294 K on a PerkinElmer Lambda 45 spectrometer. Elemental analyses were performed at the Faculty of Chemistry, University of Lodz, Poland. The HPLC-MS analysis was performed using a Shimadzu Nexera XR system equipped with an SPD-M40 and an LCMS-2020 detector on a Phenomenex XB-C18 column (50 × 4.6 mm, 2.1 mm, 1.7 μ m) using a

mixture of 55% water with 0.01% HCOOH (eluent A), 22.5% methanol with 0.01% HCOOH (eluent B), and 22.5% acetonitrile with 0.01% HCOOH (eluent C) with a flow rate of 0.4 mL·min⁻¹.

General Procedure. To a solution of (R)-1 or (S)-1 (1 equiv) in anhydrous ethanol (12 mL), pyridine-2-carbaldehyde (2 equiv) was added and the resulting solution was refluxed under argon conditions for 1 h. Next, the [LMCl₂]₂ dimer (M = Rh/Ir, L = Cp* (Cp* = η^5 -1,2,3,4,5-pentamethylcyclopentadienyl) or M = Ru/Os, L = cym (cym = η^6 -*p*-cymene)) (0.49 equiv) was added, the mixture was cooled down to RT, and stirring was continued for an additional 3 h. The solvent was evaporated to c.a. 2 mL and methanol (3 mL) and water (10




Figure 8. KSP activity after being treated with studied compounds at 100, 300, and 1000 nM concentrations.




Figure 9. ROS generation in SW620 cells exposure to the studied compounds (1 μ M). Ctrl expressed as 100%, cells in DMEM contained 0.1% DMSO as the control; verapamil (VER): cells in DMEM contained 0.1% DMSO and 10 μ M VER as an ABC inhibitor to exclude the potential activity of ABC proteins. Results are presented as mean \pm SEM, $n = 3$. No statistically significant differences were observed compared to the VER sample, (R)-1 or (S)-1 ($P < 0.05$, one-way ANOVA followed by the *posthoc* Tukey test).

mL) were added, followed by a saturated solution of KPF₆ (5 mL). The precipitant was filtrated off, washed with water (3 \times 10 mL), and dried. The products were purified by crystallization from the methanol/diethyl ether mixture.

3a [(*cym*)Ru((*R*)-2)Cl]PF₆. Compound 3a was synthesized in 69% yield (217 mg) according to the general procedure starting from 130 mg (0.38 mmol) of (R)-1, 79 mg (70 μ L, 0.74 mmol) of pyridine-2-carbaldehyde, and 114 mg (0.19 mmol) of [(*cym*)RuCl₂]₂. Elemental analysis calculated for C₃₅H₃₇Cl₂F₆N₄OPRu (846.64 g/mol) C 49.65, H 4.41, N 6.62; found C 49.37, H 4.61, N 6.85. HPLC-MS $\tau_1 = 3.50$ min calculated for C₃₅H₃₇Cl₂N₄ORu⁺ [M-PF₆]⁺ $m/z = 701.1$; found $m/z = 701.4$, $\tau_2 = 5.22$ min calculated for C₃₅H₃₇Cl₂N₄ORu⁺ [M-PF₆]⁺ $m/z = 701.1$; found $m/z = 701.0$. ¹H NMR (600 MHz, CD₂Cl₂) δ 9.29 (d, $J = 5.4$ Hz, 1H, CH^{Ar}), 9.27 (d, $J = 5.5$ Hz, 0.2H, CH^{Ar}), 9.21 (s, 0.2H, CH^{Ar}), 8.45 (s, 1H, CH^{imine}), 8.33 (d, $J = 8.5$ Hz, 1H, CH^{Ar}), 8.24 (d, $J = 7.0$ Hz, 1H, CH^{Ar}), 8.20–8.18 (m, 1H, CH^{Ar}), 8.15–8.11 (m, 0.4H, CH^{Ar}), 7.92 (d, $J = 1.9$ Hz, 1H, CH^{Ar}), 7.80–7.78 (m, 1H, CH^{Ar}), 7.75–7.72 (m, 0.2H, CH^{Ar}), 7.63 (d, $J = 1.9$ Hz, 0.2H, CH^{Ar}), 7.61 (dd, $J = 8.5, 2.0$ Hz, 1H, CH^{Ar}), 7.48–

7.44 (m, 0.6H, CH^{Ar}), 7.38 (t, $J = 7.4$ Hz, 2H, CH^{Ar}), 7.32 (t, $J = 7.1$ Hz, 2H, CH^{Ar}), 7.09 (d, $J = 7.5$ Hz, 2H, CH^{Ar}), 6.09 (d, $J = 16.7$ Hz, 0.2H, CH₂Ph), 5.96 (d, $J = 6.7$ Hz, 0.2H, 4-CH₃C₆H₄CH(CH₃)₂), 5.92 (br s, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 5.87 (d, $J = 6.0$ Hz, 0.2H, 4-CH₃C₆H₄CH(CH₃)₂), 5.80 (d, $J = 17.3$ Hz, 1H, CH₂Ph), 5.71 (br s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.66 (d, $J = 6.2$ Hz, 0.4H, 4-CH₃C₆H₄CH(CH₃)₂), 5.48 (d, $J = 5.9$ Hz, 0.2H, NCH-CH(CH₃)₂), 5.41 (d, $J = 10.3$ Hz, 0.2H, 4-CH₃C₆H₄CH(CH₃)₂), 5.23 (d, $J = 16.6$ Hz, 0.2H, CH₂Ph), 4.58 (d, $J = 10.0$ Hz, 1H, H-1'), 4.35 (d, $J = 17.3$ Hz, 1H, CH₂Ph), 3.23–3.17 (m, 1H, H-2'), 2.98–2.93 (m, 0.2H, CH(CH₃)₂), 2.60–2.56 (m, 0.2H, CH(CH₃)₂), 2.45–2.40 (m, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 2.38 (s, 0.6H, 4-CH₃C₆H₄CH(CH₃)₂), 1.84 (s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 1.21 (d, $J = 6.7$ Hz, 0.6H, 4-CH₃C₆H₄CH(CH₃)₂), 1.07 (d, $J = 6.9$ Hz, 0.6H, 4-CH₃C₆H₄CH(CH₃)₂), 1.03–0.99 (m, 7H, 4-CH₃C₆H₄CH(CH₃)₂ superimposed with H-3'), 0.89 (d, $J = 6.3$ Hz, 3H, H-3'), 0.86 (d, $J = 7.0$ Hz, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 0.55 (d, $J = 6.5$ Hz, 0.6H, 4-CH₃C₆H₄CH(CH₃)₂). ¹³C{¹H} NMR (151 MHz, CD₂Cl₂) δ 170.7 (CH^{imine}), 161.5 (C^{IV}), 156.0 (CH^{Ar}), 153.3 (C^{IV}), 153.0 (C^{IV}), 147.4 (C^{IV}), 141.4 (C^{IV}), 140.3 (CH^{Ar}), 136.2 (C^{IV}), 131.2 (CH^{Ar}), 130.3 (CH^{Ar}), 129.9 (CH^{Ar}), 129.8 (CH^{Ar}), 129.2 (CH^{Ar}), 128.6 (CH^{Ar}), 127.1 (CH^{Ar}), 127.0 (CH^{Ar}), 126.3 (CH^{Ar}), 120.2 (C^{IV}), 46.6 (CH₂), 32.0 (4-CH₃C₆H₄CH(CH₃)₂), 31.2 (C-2'), 22.9 (4-CH₃C₆H₄CH(CH₃)₂), 21.9 (4-CH₃C₆H₄CH(CH₃)₂), 20.4 (C-3'), 19.8 (C-3'), 19.2 (4-CH₃C₆H₄CH(CH₃)₂).

3b [(*cym*)Os((*R*)-2)Cl]PF₆. Compound 3b was synthesized in 37% yield (128 mg) according to the general procedure starting from 130 mg (0.38 mmol) of (R)-1, 79 mg (70 μ L, 0.74 mmol) of pyridine-2-carbaldehyde, and 148 mg (0.19 mmol) of [(*cym*)OsCl₂]₂. Elemental analysis calculated for C₃₅H₃₇Cl₂F₆N₄OsP (935.80 g/mol) C 44.92, H 3.99, N 5.99; found C 44.68, H 3.96, N 6.13. HPLC-MS $\tau_1 = 4.23$ min calculated for C₃₅H₃₇Cl₂N₄Os⁺ [M-PF₆]⁺ $m/z = 791.2$; found $m/z = 791.3$, $\tau_2 = 7.06$ min calculated for C₃₅H₃₇Cl₂N₄Os⁺ [M-PF₆]⁺ $m/z = 791.2$; found $m/z = 791.2$. ¹H NMR (600 MHz, CD₂Cl₂) δ 9.62 (s, 0.2H, CH^{imine}), 9.20 (d, $J = 5.5$ Hz, 1H, CH^{Ar}), 8.92 (s, 1H, CH^{imine}), 8.40 (d, $J = 7.4$ Hz, 1H, CH^{Ar}), 8.32 (d, $J = 8.5$ Hz, 1H, CH^{Ar}), 8.28 (d, $J = 7.8$ Hz, 0.2H, CH^{Ar}), 8.19 (d, $J = 8.6$ Hz, 0.3H, CH^{Ar}), 8.16–8.14 (m, 1H, CH^{Ar}), 8.10–8.09 (m, 0.3H, CH^{Ar}), 7.90 (d, $J = 1.9$ Hz, 1H, CH^{Ar}), 7.74–7.71 (m, 1H, CH^{Ar}), 7.68–7.66 (m, 0.6H, CH^{Ar}), 7.61 (dd, $J = 8.4, 2.0$ Hz, 1H, CH^{Ar}), 7.47–7.45 (m, 1H, CH^{Ar}), 7.40 (t, $J = 7.5$ Hz, 2H, CH^{Ar}), 7.34 (t, $J = 7.4$ Hz, 1H, CH^{Ar}), 7.30–7.27 (m, 1H, CH^{Ar}), 7.13 (d, $J = 7.5$ Hz, 2H, CH^{Ar}), 6.24 (d, $J = 5.9$ Hz, 0.3H, 4-CH₃C₆H₄CH(CH₃)₂), 6.20 (d, $J = 5.6$ Hz, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 6.06 (d, $J = 16.6$ Hz, 0.4H, CH₂Ph), 5.96 (br s, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 5.93–5.85 (m, 2H, 4-CH₃C₆H₄CH(CH₃)₂), 5.81 (d, $J = 17.0$ Hz, 1H, CH₂Ph), 5.70 (d, $J = 5.5$ Hz, 0.3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.41 (d, $J = 10.3$ Hz, 0.2H, H-1'), 5.14 (d, $J = 16.5$ Hz, 0.3H, CH₂Ph), 4.80 (d, $J = 9.9$ Hz, 1H, H-1'), 4.52 (d, $J = 13.6$ Hz, 1H, CH₂Ph), 3.16–3.10 (m, 1H, H-2'), 2.99–2.95 (m, 0.25H, H-2'), 2.91 (s, 0.1H), 2.82 (s, 0.1H), 2.50–2.46 (m, 0.2H), 2.43 (s, 0.7H, 4-CH₃C₆H₄CH(CH₃)₂), 2.34–2.27 (m, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 1.90 (s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 1.18 (d, $J = 6.6$ Hz, 1H, H-3'), 1.08 (d, $J = 6.9$ Hz, 0.8H), 1.00 (d, $J = 6.9$ Hz, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 0.97 (d, $J = 6.8$ Hz, 3H, H-3'), 0.89 (d, $J = 6.1$ Hz, 3H, H-3'), 0.78 (d, $J = 6.9$ Hz, 3H, 4-

CH₃C₆H₄CH(CH₃)₂), 0.53 (d, *J* = 6.5 Hz, 0.7H, H-3'). ¹³C{¹H} NMR (151 MHz, CD₂Cl₂) δ 172.8 (CH^{imine}), 161.5 (C^{IV}), 155.5 (CH^{Ar}), 154.7 (C^{IV}), 152.8 (C^{IV}), 147.3 (C^{IV}), 141.5 (C^{IV}), 140.3 (CH^{Ar}), 136.1 (C^{IV}), 131.1 (CH^{Ar}), 131.1 (C^{IV}), 129.9 (CH^{Ar}), 129.8 (CH^{Ar}), 129.3 (CH^{Ar}), 128.7 (CH^{Ar}), 127.3 (CH^{Ar}), 127.1 (CH^{Ar}), 126.4 (CH^{Ar}), 120.2 (C^{IV}), 83.6 (NCH-CH(CH₃)₂), 80.8 (4-CH₃C₆H₄CH(CH₃)₂), 76.9 (4-CH₃C₆H₄CH(CH₃)₂), 73.9 (4-CH₃C₆H₄CH(CH₃)₂), 46.9 (CH₂Ph), 32.2 (4-CH₃C₆H₄CH(CH₃)₂), 31.4 (NCH-CH(CH₃)₂), 23.5 (4-CH₃C₆H₄CH(CH₃)₂), 21.9 (4-CH₃C₆H₄CH(CH₃)₂), 20.5 (NCH-CH(CH₃)₂), 19.8 (4-CH₃C₆H₄CH(CH₃)₂), 19.1 (4-CH₃C₆H₄CH(CH₃)₂).

3c [(Cp*)Rh((R)-2)Cl]PF₆. Compound **3c** was synthesized in 69% yield (536 mg) according to the general procedure starting from 313 mg (0.91 mmol) of (R)-1, 195 mg (174 μL, 1.82 mmol) of pyridine-2-carbaldehyde, and 277 mg (0.45 mmol) of [Cp*⁺RhCl₂]₂. Elemental analysis calculated for C₃₅H₃₈Cl₂F₆N₄OPRh (849.49 g/mol) C 49.49, H 4.51, N 6.60; found C 49.49, H 4.50, N 6.60. HPLC-MS τ₁ = 2.67 min calculated for C₃₅H₃₈Cl₂N₄ORh⁺ [M-PF₆]⁺ *m/z* = 703.1; found *m/z* = 703.5, τ₂ = 4.29 min calculated for C₃₅H₃₈Cl₂N₄ORh⁺ [M-PF₆]⁺ *m/z* = 703.1; found *m/z* = 703.5. ¹H NMR (600 MHz, THF-*d*₈) δ 10.76 (s, 0.1H, CH), 9.27 (s, 1H, CH^{imine}), 8.89 (d, *J* = 5.4 Hz, 1H, CH^{Ar}), 8.86 (d, *J* = 5.5 Hz, 0.1H, CH^{Ar}), 8.66 (s, 0.1H, CH^{Ar}), 8.24 (d, *J* = 7.4 Hz, 1H, CH^{Ar}), 8.19 (t, *J* = 7.8 Hz, 1H, CH^{Ar}), 8.15 (d, *J* = 8.5 Hz, 1H, CH^{Ar}), 7.87 (d, *J* = 1.8 Hz, 0.2H, CH^{Ar}), 7.84 (t, *J* = 6.4 Hz, 1H, CH^{Ar}), 7.73 (d, *J* = 1.7 Hz, 1H, CH^{Ar}), 7.56 (dd, *J* = 8.6, 2.0 Hz, 0.1H, CH^{Ar}), 7.47 (dd, *J* = 8.6, 2.0 Hz, 1H, CH^{Ar}), 7.39 (t, *J* = 7.5 Hz, 2H, CH^{Ar}), 7.32–7.28 (m, 3.5H, CH^{Ar}), 7.23 (d, *J* = 7.2 Hz, 0.1H, CH^{Ar}), 7.20 (d, *J* = 7.9 Hz, 0.3H, CH^{Ar}), 5.91 (d, *J* = 16.9 Hz, 1H, CH₂Ph), 5.80 (d, *J* = 17.4 Hz, 0.1H, CH₂Ph), 5.33 (d, *J* = 17.1 Hz, 1H, CH₂Ph), 5.13 (d, *J* = 8.7 Hz, 1H, H-1'), 3.08–3.02 (m, 1H, H-2'), 2.39 (s, 0.4H), 1.73 (s, 15H, Cp*-CH₃), 1.63 (s, 2H, Cp*-CH₃), 1.13 (d, *J* = 6.7 Hz, 3H, H-3'), 0.95 (d, *J* = 6.6 Hz, 3H, H-3'). ¹³C{¹H} NMR (151 MHz, THF-*d*₈) δ 170.4 (CH^{imine}), 161.5 (C^{IV}), 157.0 (C^{IV}), 154.7 (C^{IV}), 153.6 (CH^{Ar}), 148.2 (C^{IV}), 140.8 (CH^{Ar}), 140.7 (C^{IV}), 137.0 (C^{IV}), 131.1 (CH^{Ar}), 130.7 (CH^{Ar}), 129.6 (CH^{Ar}), 129.5 (CH^{Ar}), 129.3 (CH^{Ar}), 128.3 (CH^{Ar}), 128.3 (CH^{Ar}), 127.6 (CH^{Ar}), 127.1 (CH^{Ar}), 120.4 (C^{IV}), 98.6 (d, *J*_{C-Rh} = 7.7 Hz, Cp*), 73.2 (C-1'), 48.2 (CH₂Ph), 35.1 (C-2'), 19.9 (C-3'), 18.8 (C-3'), 9.1 (Cp*-CH₃).

3d [(Cp*)Ir((R)-2)Cl]PF₆. Compound **3d** was synthesized in 73% yield (593 mg) according to the general procedure starting from 296 mg (0.87 mmol) of (R)-1, 185 mg (165 μL, 1.73 mmol) of pyridine-2-carbaldehyde, and 338 mg (0.42 mmol) of [Cp*⁺IrCl₂]₂. Elemental analysis calculated for C₃₅H₃₈Cl₂F₆IrN₄OP (938.80 g/mol) C 44.78, H 4.08, N 5.97; found C 44.83, H 4.20, N 5.97. HPLC-MS τ₁ = 3.65 min calculated for C₃₅H₃₈Cl₂N₄OIr⁺ [M-PF₆]⁺ *m/z* = 793.2; found *m/z* = 793.4, τ₂ = 7.45 min calculated for C₃₅H₃₈Cl₂N₄OIr⁺ [M-PF₆]⁺ *m/z* = 793.2; found *m/z* = 793.6. ¹H NMR (600 MHz, THF-*d*₈) δ 9.83 (s, 1H, CH^{imine}), 9.14 (s, 0.4H), 8.86 (d, *J* = 5.4 Hz, 1H, CH^{Ar}), 8.84 (d, *J* = 5.5 Hz, 0.4H, CH^{Ar}), 8.42 (d, *J* = 7.6 Hz, 1H, CH^{Ar}), 8.22 (d, *J* = 8.5 Hz, 0.6H, CH^{Ar}), 8.17 (t, *J* = 7.6 Hz, 1H, CH^{Ar}), 8.14 (d, *J* = 8.5 Hz, 1H, CH^{Ar}), 7.87 (d, *J* = 2.0 Hz, 0.4H, CH^{Ar}), 7.84–7.80 (m, 1.5H, CH^{Ar}), 7.79 (d, *J* = 2.0 Hz, 1H, CH^{Ar}), 7.57 (dd, *J* = 8.6, 2.0 Hz, 0.5H, CH^{Ar}), 7.47 (dd, *J* = 8.5, 2.0 Hz, 1H, CH^{Ar}), 7.38 (t, *J* = 7.5

Hz, 2H, CH^{Ar}), 7.32–7.26 (m, 4H, CH^{Ar}), 7.26–7.22 (m, 1H, CH^{Ar}), 7.19 (d, *J* = 7.5 Hz, 1H, CH^{Ar}), 5.87 (d, *J* = 17.1 Hz, 1H, CH₂Ph), 5.78 (d, *J* = 17.2 Hz, 0.4H), 5.24 (d, *J* = 17.1 Hz, 1H, CH₂Ph), 5.15 (d, *J* = 9.3 Hz, 1H, H-1'), 3.20–3.13 (m, 1H, H-2'), 2.95–2.89 (m, 0.4H, H-2'), 1.69 (s, 15H, Cp*-CH₃), 1.60 (s, 7H, Cp*-CH₃), 1.16 (d, *J* = 6.7 Hz, 3H, H-3'), 0.92 (d, *J* = 6.6 Hz, 3H, H-3'). ¹³C{¹H} NMR (151 MHz, THF-*d*₈) δ 172.0 (CH^{imine}), 161.3 (C^{IV}), 157.0 (C^{IV}), 156.2 (C^{IV}), 153.1 (CH^{Ar}), 148.2 (C^{IV}), 141.0 (CH^{Ar}), 140.8 (CH^{Ar}), 136.7 (C^{IV}), 131.3 (CH^{Ar}), 131.2 (CH^{Ar}), 129.6 (CH^{Ar}), 129.4 (CH^{Ar}), 129.3 (CH^{Ar}), 128.4 (CH^{Ar}), 128.3 (CH^{Ar}), 128.2 (CH^{Ar}), 127.7 (CH^{Ar}), 127.0 (CH^{Ar}), 120.3 (C^{IV}), 91.3 (Cp*), 74.8 (C-1'), 48.1 (CH₂Ph), 35.9 (C-2'), 19.9 (C-3'), 19.2 (C-3'), 8.80 (Cp*-CH₃).

4a [(cym)Ru((S)-2)Cl]PF₆. Compound **4a** was synthesized in 68% yield (215 mg) according to the general procedure starting from 130 mg (0.38 mmol) of (S)-1, 79 mg (70 μL, 0.74 mmol) of pyridine-2-carbaldehyde, and 114 mg (0.19 mmol) of [(cym)RuCl₂]₂. Elemental analysis calculated for C₃₅H₃₇Cl₂F₆N₄OPRu (846.64 g/mol) C 49.65, H 4.41, N 6.62; found C 49.41, H 4.59, N 6.80. HPLC-MS τ₁ = 3.39 min calculated for C₃₅H₃₇Cl₂N₄ORu⁺ [M-PF₆]⁺ *m/z* = 701.1; found *m/z* = 701.3, τ₂ = 5.07 min calculated for C₃₅H₃₇Cl₂N₄ORu⁺ [M-PF₆]⁺ *m/z* = 701.1; found *m/z* = 700.8. ¹H NMR (600 MHz, CD₂Cl₂) δ 9.29 (d, *J* = 5.4 Hz, 1H, CH^{Ar}), 9.27 (d, *J* = 5.6 Hz, 0.2H, CH^{Ar}), 9.21 (s, 0.2H, CH^{imine}), 8.45 (s, 1H, CH^{imine}), 8.33 (d, *J* = 8.5 Hz, 1H, CH^{Ar}), 8.24 (d, *J* = 7.1 Hz, 1H, CH^{Ar}), 8.19 (t, *J* = 3.8 Hz, 1H, CH^{Ar}), 8.15–8.11 (m, 0.4H, CH^{Ar}), 7.92 (d, *J* = 1.9 Hz, 1H, CH^{Ar}), 7.80–7.78 (m, 1H, CH^{Ar}), 7.74–7.72 (m, 0.2H, CH^{Ar}), 7.63 (d, *J* = 1.8 Hz, 0.2H, CH^{Ar}), 7.61 (dd, *J* = 8.6, 2.0 Hz, 1H, CH^{Ar}), 7.48–7.44 (m, 0.7H, CH^{Ar}), 7.41 (d, *J* = 7.4 Hz, 0.2H, CH^{Ar}), 7.38 (t, *J* = 7.4 Hz, 2H, CH^{Ar}), 7.32 (t, *J* = 6.8 Hz, 2H, CH^{Ar}), 7.09 (d, *J* = 7.5 Hz, 2H, CH^{Ar}), 6.09 (d, *J* = 16.9 Hz, 0.2H, CH₂Ph), 5.96 (d, *J* = 6.5 Hz, 0.3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.92 (br s, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 5.87 (d, *J* = 6.0 Hz, 0.3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.80 (d, *J* = 16.8 Hz, 1H, CH₂Ph), 5.71 (br s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.66 (d, *J* = 6.4 Hz, 0.3H, 4-CH₃C₆H₄CH(CH₃)₂), 5.48 (d, *J* = 5.9 Hz, 0.2H, H-1'), 5.41 (d, *J* = 10.1 Hz, 0.2H, H-1'), 5.23 (d, *J* = 16.5 Hz, 0.2H, CH₂Ph), 4.58 (d, *J* = 9.2 Hz, 1H, H-1'), 4.35 (d, *J* = 14.5 Hz, 1H, CH₂Ph), 3.23–3.17 (m, 1H, H-2'), 2.98–2.94 (m, 0.2H, H-2'), 2.60–2.55 (m, 0.2H, 4-CH₃C₆H₄CH(CH₃)₂), 2.45–2.40 (m, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 2.38 (s, 0.6H, 4-CH₃C₆H₄CH(CH₃)₂), 1.84 (s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 1.21 (d, *J* = 6.6 Hz, 0.8H, H-3'), 1.07 (d, *J* = 6.9 Hz, 0.7H, 4-CH₃C₆H₄CH(CH₃)₂), 1.03–0.99 (m, 7H, H-3', superimposed with 4-CH₃C₆H₄CH(CH₃)₂), 0.89 (d, *J* = 6.3 Hz, 3H, H-3'), 0.86 (d, *J* = 7.0 Hz, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 0.55 (d, *J* = 6.5 Hz, 0.7H, H-3'). ¹³C{¹H} NMR (151 MHz, CD₂Cl₂) δ 170.7 (CH^{imine}), 161.5 (C^{IV}), 156.0 (CH^{Ar}), 153.3 (C^{IV}), 153.0 (C^{IV}), 147.4 (C^{IV}), 141.4 (C^{IV}), 140.3 (CH^{Ar}), 136.2 (C^{IV}), 131.2 (CH^{Ar}), 130.3 (CH^{Ar}), 129.9 (CH^{Ar}), 129.8 (CH^{Ar}), 129.2 (CH^{Ar}), 128.5 (CH^{Ar}), 127.1 (CH^{Ar}), 127.0 (CH^{Ar}), 126.3 (CH^{Ar}), 120.2 (C^{IV}), 82.9 (C-1'), 79.5 (4-CH₃C₆H₄CH(CH₃)₂), 47.9 (CH₂Ph), 46.6 (CH₂Ph), 32.0 (4-CH₃C₆H₄CH(CH₃)₂), 31.3 (C-2'), 22.9 (C-H), 22.7 (C-H), 22.6 (C-H), 22.3 (C-H), 21.9 (4-CH₃C₆H₄CH(CH₃)₂), 20.4 (C-3'), 19.8 (4-CH₃C₆H₄CH(CH₃)₂), 19.2 (4-CH₃C₆H₄CH(CH₃)₂).

4b [(cym)Os((S)-2)Cl]PF₆. Compound **4b** was synthesized in 41% yield (144 mg) according to the general procedure

starting from 130 mg (0.38 mmol) of (S)-1, 79 mg (70 μ L, 0.74 mmol) of pyridine-2-carbaldehyde, and 149 mg (0.19 mmol) of [(cym)OsCl₂]₂. Elemental analysis calculated for C₃₅H₃₇Cl₂F₆N₄OOSp (935.80 g/mol) C 44.92, H 3.99, N 5.99; found C 44.75, H 4.09, N 5.78. HPLC-MS τ_1 = 4.24 min calculated for C₃₅H₃₇Cl₂N₄OOS⁺ [M-PF₆]⁺ m/z = 791.2; found m/z = 791.4, τ_2 = 7.04 min calculated for C₃₅H₃₇Cl₂N₄OOS⁺ [M-PF₆]⁺ m/z = 791.2; found m/z = 791.6. ¹H NMR (600 MHz, CD₂Cl₂) δ 9.62 (s, 0.25H, CH^{Ar}), 9.20 (d, J = 5.5 Hz, 1H, CH^{Ar}), 8.91 (s, 1H, CH^{imine}), 8.40 (d, J = 7.5 Hz, 1H, CH^{Ar}), 8.31 (d, J = 8.5 Hz, 1H, CH^{Ar}), 8.27 (d, J = 7.8 Hz, 0.25H, CH^{Ar}), 8.19 (d, J = 8.5 Hz, 0.25H, CH^{Ar}), 8.17–8.14 (m, 1H, CH^{Ar}), 8.11–8.08 (m, 0.25H, CH^{Ar}), 7.90 (d, J = 1.9 Hz, 1H, CH^{Ar}), 7.74–7.72 (m, 1H, CH^{Ar}), 7.68–7.66 (m, 0.5H, CH^{Ar}), 7.61 (dd, J = 8.2, 2.0 Hz, 1H, CH^{Ar}), 7.47–7.45 (m, 0.75H, CH^{Ar}), 7.39 (t, J = 7.5 Hz, 2H, CH^{Ar}), 7.34 (t, J = 7.4 Hz, 1H, CH^{Ar}), 7.29 (d, J = 7.5 Hz, 0.5H, CH^{Ar}), 7.12 (d, J = 7.5 Hz, 2H, CH^{Ar}), 6.24 (d, J = 6.1 Hz, 0.4H, 4-CH₃C₆H₄CH(CH₃)₂), 6.19 (d, J = 5.5 Hz, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 6.06 (d, J = 16.5 Hz, 0.4H, CH₂Ph), 5.96 (br s, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 5.92–5.84 (m, 2H, 4-CH₃C₆H₄CH(CH₃)₂), 5.81 (d, J = 16.7 Hz, 1H, CH₂Ph), 5.69 (d, J = 5.5 Hz, 0.25H, 4-CH₃C₆H₄CH(CH₃)₂), 5.40 (d, J = 10.4 Hz, 0.25H, NCH–CH(CH₃)₂), 5.13 (d, J = 16.4 Hz, 0.25H, CH₂Ph), 4.78 (d, J = 9.9 Hz, 1H, NCH–CH(CH₃)₂), 4.50 (d, J = 16.2 Hz, 1H, CH₂Ph), 3.42 (s, 0.1H), 3.16–3.10 (m, 1H, NCH–CH(CH₃)₂), 3.00–2.95 (m, 0.25H, NCH–CH(CH₃)₂), 2.43 (s, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 2.32–2.27 (m, 1H, 4-CH₃C₆H₄CH(CH₃)₂), 1.90 (s, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 1.35 (d, J = 6.9 Hz, 0.25H), 1.17 (d, J = 6.7 Hz, 1H, NCH–CH(CH₃)₂), 1.07 (d, J = 6.9 Hz, 1H), 1.00 (d, J = 6.9 Hz, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 0.96 (d, J = 6.8 Hz, 3H, NCH–CH(CH₃)₂), 0.89 (d, J = 6.1 Hz, 3H, NCH–CH(CH₃)₂), 0.77 (d, J = 6.9 Hz, 3H, 4-CH₃C₆H₄CH(CH₃)₂), 0.51 (d, J = 6.6 Hz, 0.75H, NCH–CH(CH₃)₂). ¹³C{¹H} NMR (151 MHz, CD₂Cl₂) δ 172.4 (CH^{imine}), 161.1 (C^{IV}), 155.2 (CH^{Ar}), 154.2 (C^{IV}), 152.3 (C^{IV}), 146.9 (C^{IV}), 141.1 (C^{IV}), 140.0 (CH^{Ar}), 135.7 (C^{IV}), 130.8 (CH^{Ar}), 129.5 (CH^{Ar}), 129.4 (CH^{Ar}), 128.9 (CH^{Ar}), 128.2 (CH^{Ar}), 126.7 (CH^{Ar}), 126.0 (CH^{Ar}), 119.7 (C^{IV}), 88.3 (4-CH₃C₆H₄CH(CH₃)₂), 83.2 (C-1'), 46.5 (CH₂), 31.8 (4-CH₃C₆H₄CH(CH₃)₂), 30.9 (C-2'), 23.1 (4-CH₃C₆H₄CH(CH₃)₂), 21.4 (4-CH₃C₆H₄CH(CH₃)₂), 20.1 (C-3'), 19.3 (C-3'), 18.7 (4-CH₃C₆H₄CH(CH₃)₂).

4c [(Cp*)Rh(S)-2]Cl/PPF₆. Compound 4c was synthesized in 68% yield (535 mg) according to the general procedure starting from 313 mg (0.91 mmol) of (S)-1, 195 mg (174 μ L, 1.82 mmol) of pyridine-2-carbaldehyde, and 276 mg (0.45 mmol) of [Cp*⁺RhCl₂]₂. Elemental analysis calculated for C₃₅H₃₈Cl₂F₆N₄OPRh (849.49 g/mol) C 49.49, H 4.51, N 6.60; found C 49.53, H 4.49, N 6.55. HPLC-MS τ_1 = 2.79 min calculated for C₃₅H₃₈Cl₂N₄ORh⁺ [M-PF₆]⁺ m/z = 703.1; found m/z = 703.5, τ_2 = 4.20 min calculated for C₃₅H₃₈Cl₂N₄ORh⁺ [M-PF₆]⁺ m/z = 703.1; found m/z = 703.5. ¹H NMR (600 MHz, THF-*d*₈) δ 10.77 (s, 0.1H), 9.27 (s, 1H, CH^{imine}), 8.90 (d, J = 5.3 Hz, 1H, CH^{Ar}), 8.86 (d, J = 5.1 Hz, 0.1H, CH^{Ar}), 8.66 (s, 0.1H), 8.24 (d, J = 7.1 Hz, 1H, CH^{Ar}), 8.19 (t, J = 7.7 Hz, 1H, CH^{Ar}), 8.15 (d, J = 8.5 Hz, 1H, CH^{Ar}), 7.87 (d, J = 1.7 Hz, 0.2H, CH^{Ar}), 7.84 (t, J = 6.0 Hz, 1H, CH^{Ar}), 7.73 (d, J = 1.8 Hz, 1H, CH^{Ar}), 7.56 (dd, J = 8.5, 2.0 Hz, 0.1H, CH^{Ar}), 7.47 (dd, J = 8.5, 2.0 Hz, 1H, CH^{Ar}), 7.39 (t, J = 7.4 Hz, 2H, CH^{Ar}), 7.32–7.28 (m, 3.5H, CH^{Ar}), 7.23 (d, J = 7.4 Hz, 0.1H, CH^{Ar}), 7.20 (d, J = 7.7 Hz, 0.3H, CH^{Ar}), 5.91 (d, J = 16.7 Hz, 1H, CH₂Ph), 5.70 (d, J = 17.2 Hz, 0.1H,

CH₂Ph), 5.33 (d, J = 17.1 Hz, 1H, CH₂Ph), 5.13 (d, J = 8.7 Hz, 1H, H-1'), 3.08–3.02 (m, 1H, H-2'), 2.39 (s, 0.5H), 1.73 (s, 15H, Cp*–CH₃), 1.63 (s, 2H, Cp*–CH₃), 1.13–1.10 (m, 3H, H-3' superimposed with the diethyl ether signal), 0.95 (d, J = 6.6 Hz, 3H, H-3'). ¹³C{¹H} NMR (151 MHz, THF-*d*₈) δ 170.4 (CH^{imine}), 161.5 (C^{IV}), 154.7 (C^{IV}), 153.6 (CH^{Ar}), 148.2 (C^{IV}), 140.8 (CH^{Ar}), 140.7 (C^{IV}), 137.0 (C^{IV}), 131.1 (CH^{Ar}), 130.6 (CH^{Ar}), 129.6 (CH^{Ar}), 129.5 (CH^{Ar}), 129.3 (CH^{Ar}), 128.3 (CH^{Ar}), 128.3 (CH^{Ar}), 127.6 (CH^{Ar}), 127.1 (CH^{Ar}), 120.4 (C^{IV}), 98.6 (d, J_{Rh-C} = 7.8 Hz, Cp*), 73.2 (C-1'), 48.2 (CH₂Ph), 35.1 (C-2'), 19.9 (C-3'), 18.8 (C-3'), 9.1 (Cp*–CH₃).

4d [(Cp*)Ir(S)-2]Cl/PPF₆. Compound 4d was synthesized in 72% yield (413 mg) according to the general procedure starting from 208 mg (0.61 mmol) of (S)-1, 131 mg (115 μ L, 1.22 mmol) of pyridine-2-carbaldehyde, and 237 mg (0.30 mmol) of [Cp*⁺IrCl₂]₂. Elemental analysis calculated for C₃₅H₃₈Cl₂F₆N₄OPIr (938.80 g/mol) C 44.78, H 4.08, N 5.97; found C 44.69, H 4.05, N 5.86. HPLC-MS τ_1 = 3.81 min calculated for C₃₅H₃₈Cl₂N₄OIr⁺ [M-PF₆]⁺ m/z = 793.2; found m/z = 793.6, τ_2 = 7.53 min calculated for C₃₅H₃₈Cl₂N₄OIr⁺ [M-PF₆]⁺ m/z = 793.2; found m/z = 793.5. ¹H NMR (600 MHz, THF-*d*₈) δ 9.82 (s, 0.7H, CH^{imine}), 9.14 (s, 1H, CH^{imine}), 8.87 (d, J = 5.4 Hz, 0.7H, CH^{Ar}), 8.84 (d, J = 5.4 Hz, 1H, CH^{Ar}), 8.41 (d, J = 7.7 Hz, 0.7H, CH^{Ar}), 8.22 (d, J = 8.5 Hz, 1.3H, CH^{Ar}), 8.18–8.16 (m, 1.4H, CH^{Ar}), 8.14 (d, J = 8.5 Hz, 1H, CH^{Ar}), 7.87 (d, J = 1.9 Hz, 1H, CH^{Ar}), 7.83–7.80 (m, 1.7H, CH^{Ar}), 7.79 (d, J = 1.9 Hz, 0.7H, CH^{Ar}), 7.57 (dd, J = 8.6, 1.9 Hz, 1H, CH^{Ar}), 7.47 (dd, J = 8.5, 2.0 Hz, 0.7H, CH^{Ar}), 7.38 (t, J = 7.5 Hz, 1.5H, CH^{Ar}), 7.33–7.28 (m, 4H, CH^{Ar}), 7.24 (t, J = 7.3 Hz, 1H, CH^{Ar}), 7.19 (d, J = 7.5 Hz, 2H, CH^{Ar}), 5.87 (d, J = 17.0 Hz, 0.7H, CH₂Ph), 5.78 (d, J = 17.1 Hz, 1H, CH₂Ph), 5.24 (d, J = 17.1 Hz, 0.8H, CH₂Ph), 5.15 (d, J = 9.3 Hz, 1H, H-1'), 4.74 (br s, 0.7H, CH₂Ph), 3.19–3.13 (m, 0.7H, H-2'), 2.95–2.87 (m, 1H, H-2'), 1.70 (s, 11.5H, Cp*–CH₃), 1.61 (s, 15H, Cp*–CH₃), 1.19 (br s, 3H, H-3') superimposed with 1.16 (d, J = 6.7 Hz, 3H, H-3'), 0.93 (d, J = 6.6 Hz, 2.3H, H-3'). ¹³C{¹H} NMR (151 MHz, THF-*d*₈) δ 172.0 (CH^{imine}), 161.4 (C^{IV}), 161.3 (C^{IV}), 156.9 (C^{IV}), 156.2 (C^{IV}), 153.1 (CH^{Ar}), 152.7 (CH^{Ar}), 148.2 (C^{IV}), 147.9 (C^{IV}), 141.1 (CH^{Ar}), 140.8 (CH^{Ar}), 140.6 (C^{IV}), 136.7 (C^{IV}), 131.3 (CH^{Ar}), 131.2 (CH^{Ar}), 129.6 (CH^{Ar}), 129.4 (CH^{Ar}), 129.3 (CH^{Ar}), 128.7 (CH^{Ar}), 128.4 (CH^{Ar}), 128.3 (CH^{Ar}), 128.2 (CH^{Ar}), 127.7 (CH^{Ar}), 127.0 (CH^{Ar}), 126.7 (CH^{Ar}), 121.1 (C^{IV}), 120.4 (C^{IV}), 91.4 (Cp*), 91.3 (Cp*), 74.8 (C-1'), 48.1 (CH₂Ph), 35.9 (C-2'), 20.2 (C-3'), 19.9 (C-3'), 19.2 (C-3'), 19.1 (C-3'), 8.8 (Cp*–CH₃), 8.8 (Cp*–CH₃).

Stability Studies. The stability of 3a–d was studied in the presence of L-cysteine or L-histidine. 3a–d were dissolved in DMSO and added to 0.2 mM aqueous solution of L-cysteine or L-histidine to achieve the complex concentration of 20 μ M while keeping the DMSO concentration at 0.5 vol %. UV–vis spectra were recorded over 2 h with 10 min intervals. HPLC-MS analysis with them using UV–vis spectroscopy and HPLC-MS analysis were performed on a Phenomenex XB-C18 column (50 \times 4.6 mm, 2.1 mm, 1.7 μ m) using a mixture of 55% water with 0.01% HCOOH (eluent A), 22.5% methanol with 0.01% HCOOH (eluent B), and 22.5% acetonitrile with 0.01% HCOOH (eluent C) with a flow rate of 0.4 mL·min⁻¹.

Cell Lines. Cell lines used in this study were purchased from the American Type Culture Collection via LGC Standards. Human normal lung fibroblasts (MRC-5), alveolar basal epithelial cell adenocarcinoma (A549), colorectal

adenocarcinoma (Colo205), hepatocellular carcinoma (HepG2), breast adenocarcinoma (MCF7), and colorectal adenocarcinoma (SW620) and its MDR variants⁵⁵ were cultured in standard conditions (37 °C, 5% CO₂, 100% relative humidity) in high glucose DMEM medium supplemented with GlutaMax, HEPES (ThermoFisher Scientific) and 10% fetal bovine serum (EURx, Poland). All cell lines were tested for *Mycoplasma* contamination using a MycoProbe mycoplasma detection kit (R&D System).

Assaying the Antiproliferative Potential. For this purpose, neutral red uptake assay was performed. 10⁴ of cells were seeded per well of a 96-well plate and left overnight to allow cells to attach to the surface. Then, the cells were exposed to a desired concentration of tested compounds. Stock solutions were prepared in DMSO and were used immediately after preparation. The final concentration of DMSO was constant and nontoxic (0.1% v/v). After 70 h of culture, neutral red was added to the final concentration of 1 mM. After 2 h of incubation with the dye, the medium was aspirated and cells were washed with ice-cold PBS. The dye was released using 100 μL of the solubilizer (1% acetic acid in 50% ethanol) on an orbital shaker (10 min). The absorbance at 540 nm was measured using an EnVision multilabel plate reader (PerkinElmer). The results were presented as a percentage of control. The IC₉₀ and IC₅₀ parameters were calculated using GraphPad Prism v9 software using the five-parameter non-linear logistic regression model.

Cell Cycle. SW620 and SW620E cells lines (vulnerable and resistant variants, respectively) were seeded in 6-well plates at a density of 10⁵ cells per well. After the time necessary for the cells to attach to the surface, the cells were treated with tested compounds at a concentration equal to IC₉₀ for parent compounds (15 nM for (R) series and 23 nM for (S) series). After 24 h, the cells were trypsinized and fixed with ice-cold 70% v/v ethanol. The cells were stained with 75 μM propidium iodide with 50 Kunitz units of RNase A in PBS for 30 min at 37 °C. All samples were analyzed using a LSRII flow cytometer (Becton Dickinson) at a PE channel (526/26 nm). Cell cycle phase distribution was determined using a built-in cell cycle module (Watson pragmatic algorithm) by FlowJo 7.6.1 software.

Reactive Oxygen Species Assay. Dihydrorhodamine 123 oxidation was used as an indicator of intracellular ROS production. For this purpose, SW620 cells were seeded in 6-well plates at a density of 10⁵ cells per well. The cells were left overnight (time needed for them to attach to the surface). Then, 1 μM tested compounds were added along with 1 μM DHR123. Additionally, since DHR123 is a substrate of ABCB1 (which may interfere in this assay), 10 μM verapamil, an inhibitor of this protein, was added. The cells were cultured for an additional 4 h at 37 °C, and then the cells were harvested by trypsinization, resuspended in a complete medium, and analyzed using a LSRII flow cytometer (Becton Dickinson) in a FITC channel (530/30 nm). The results are presented as a percentage of control (median fluorescence in the presence of DMSO).

Kinesin ATPase Inhibition Assay. The potential kinesin modulatory activity of tested compounds was performed using a Kinesin ATPase end-point biochem kit (Cytoskeleton, Inc.). Compounds were dissolved in DMSO (the final concentration did not exceed 0.1%). The experiment was performed according to the manufacturer's instructions. One μg of tested kinesin (KSP) was used per reaction. Phosphate release was

measured at the absorbance 650 nm using an EnVision multilabel plate reader (PerkinElmer).

■ ASSOCIATED CONTENT

Data Availability Statement

The crystal structure of **4a** was deposited with CCDC and assigned deposition number 2207900. It can be accessed free of charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing at data_request@ccdc.cam.ac.uk, or by contacting the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax: + 44 1223 336033.

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.3c10482>.

Additional figures and tables illustrating the HPLC-MS analysis of final products, UV-vis spectra, copies of ¹H and ¹³C{¹H} NMR spectra, ¹H-¹³C HSQC NMR spectra and ¹H DOSY spectra, the cell cycle phase distribution table for SW620 cells, and the graphical representation of IC₅₀ values (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Michał Łomzik – Faculty of Chemistry, Department of Organic Chemistry, University of Lodz, 91-403 Łódź, Poland; orcid.org/0000-0003-4847-3520; Phone: +48(42)6355760; Email: michal.lomzik@chemia.uni.lodz.pl

Damian Płażuk – Faculty of Chemistry, Department of Organic Chemistry, University of Lodz, 91-403 Łódź, Poland; orcid.org/0000-0002-2898-6604; Phone: +48(42)6655329; Email: damian.plazuk@chemia.uni.lodz.pl

Authors

Andrzej Błaż – Faculty of Biology and Environmental Protection, Department of Oncobiology and Epigenetics, Cytometry Lab, University of Lodz, 90-236 Łódź, Poland

Daniel Tchoń – Laboratory for Structural and Biochemical Research (LBSBio), Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, 02-089 Warszawa, Poland; Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States; orcid.org/0000-0003-4798-867X

Anna Makal – Laboratory for Structural and Biochemical Research (LBSBio), Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, 02-089 Warszawa, Poland

Błażej Rychlik – Faculty of Biology and Environmental Protection, Department of Oncobiology and Epigenetics, Cytometry Lab, University of Lodz, 90-236 Łódź, Poland; orcid.org/0000-0001-8928-5900

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acsomega.3c10482>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This study was financially supported by the National Science Centre Poland (NCN) based on decision UMO-2015/17/B/ST5/02331. The authors also thank Dr. Paweł Tokarz (University of Lodz, Poland) for performing DOSY experiments.

REFERENCES

- (1) Giaquinto, A. N.; Sung, H.; Miller, K. D.; Kramer, J. L.; Newman, L. A.; Minihan, A.; Jemal, A.; Siegel, R. L. Breast Cancer Statistics, 2022. *Ca-Cancer J. Clin.* **2022**, *72*, 524–541, DOI: 10.3322/caac.21754.
- (2) De Silva, F.; Alcorn, J. A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer. *Cancers* **2022**, *14* (12), 2954.
- (3) Miller, K. D.; Nogueira, L.; Devasia, T.; Mariotto, A. B.; Yabroff, K. R.; Jemal, A.; Kramer, J.; Siegel, R. L. Cancer treatment and survivorship statistics, 2022. *Ca-Cancer J. Clin.* **2022**, *72* (5), 409–436.
- (4) Zugazagoitia, J.; Guedes, C.; Ponce, S.; Ferrer, I.; Molina-Pinelo, S.; Paz-Ares, L. Current Challenges in Cancer Treatment. *Clin. Ther.* **2016**, *38* (7), 1551–1566.
- (5) Vale, R. D. The Molecular Motor Toolbox for Intracellular Transport. *Cell* **2003**, *112* (4), 467–480.
- (6) Howard, J.; Hyman, A. A. Microtubule polymerases and depolymerases. *Curr. Opin. Cell Biol.* **2007**, *19* (1), 31–35.
- (7) Cella, D.; Peterman, A.; Hudgens, S.; Webster, K.; Socinski, M. A. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). *Cancer* **2003**, *98* (4), 822–831.
- (8) Shahin, R.; Aljamal, S. Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies. *Future Sci. OA* **2022**, *8* (3), No. FSO778, DOI: 10.2144/fsoa-2021-0116.
- (9) Chen, Y.; Hancock, W. O. Kinesin-5 is a microtubule polymerase. *Nat. Commun.* **2015**, *6* (1), No. 8160.
- (10) Mann, B. J.; Wadsworth, P. Kinesin-5 Regulation and Function in Mitosis. *Trends Cell Biol.* **2019**, *29* (1), 66–79.
- (11) Maliga, Z.; Kapoor, T. M.; Mitchison, T. J. Evidence that Monastrol Is an Allosteric Inhibitor of the Mitotic Kinesin Eg5. *Chem. Biol.* **2002**, *9* (9), 989–996.
- (12) Bongero, D.; Paoluzzi, L.; Marchi, E.; Zullo, K. M.; Neisa, R.; Mao, Y.; Escandon, R.; Wood, K.; O'Connor, O. A. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in vivo and in vitro models of aggressive large B-cell lymphoma. *Leuk. Lymphoma* **2015**, *56* (10), 2945–2952.
- (13) Novais, P.; Silva, P. M. A.; Amorim, I.; Bousbaa, H. Second-Generation Antimitotics in Cancer Clinical Trials. *Pharmaceutics* **2021**, *13* 71011.
- (14) Cox, C. D.; Coleman, P. J.; Breslin, M. J.; Whitman, D. B.; Garbaccio, R. M.; Fraley, M. E.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; et al. Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer. *J. Med. Chem.* **2008**, *51* (14), 4239–4252.
- (15) Kim, K. H.; Xie, Y.; Tytler, E. M.; Woessner, R.; Mor, G.; Alvero, A. B. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. *J. Transl. Med.* **2009**, *7* (1), 63.
- (16) Woessner, R.; Tunquist, B.; Lemieux, C.; Chlipala, E.; Jackinsky, S.; Dewolf, W., Jr.; Voegtli, W.; Cox, A.; Rana, S.; Lee, P.; Walker, D. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. *Anticancer Res.* **2009**, *29* (11), 4373–4380, DOI: 10.1186/1479-5876-7-63.
- (17) Purcell, J. W.; Davis, J.; Reddy, M.; Martin, S.; Samayoa, K.; Vo, H.; Thomsen, K.; Bean, P.; Kuo, W. L.; Ziyad, S.; et al. Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer. *Clin. Cancer Res.* **2010**, *16* (2), 566–576.
- (18) Khoury, H. J.; Garcia-Manero, G.; Borthakur, G.; Kadia, T.; Foudray, M. C.; Arellano, M.; Langston, A.; Bethelmie-Bryan, B.; Rush, S.; Litwiler, K.; et al. A phase I dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. *Cancer* **2012**, *118* (14), 3556–3564.
- (19) Carter, B. Z.; Mak, D. H.; Woessner, R.; Gross, S.; Schober, W. D.; Estrov, Z.; Kantarjian, H.; Andreeff, M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. *Leukemia* **2009**, *23* (10), 1755–1762.
- (20) Institute, N. C. SB-715992 in Treating Patients with Recurrent or Metastatic Head and Neck Cancer, 2005. <https://ClinicalTrials.gov/show/NCT00095628>.
- (21) McQuitty, R. J. Metal-based drugs. *Sci. Prog.* **2014**, *97* (Pt 1), 1–19.
- (22) Boros, E.; Dyson, P. J.; Gasser, G. Classification of Metal-Based Drugs according to Their Mechanisms of Action. *Chem.* **2020**, *6* (1), 41–60.
- (23) Allardyce, C. S.; Dyson, P. J. Metal-based drugs that break the rules. *Dalton Trans.* **2016**, *45* (8), 3201–3209.
- (24) Jaouen, G.; Vessières, A.; Top, S. Ferrocifen type anti cancer drugs. *Chem. Soc. Rev.* **2015**, *44* (24), 8802–8817.
- (25) Simović, A. R.; Masnikosa, R.; Bratsos, I.; Alessio, E. Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure. *Coord. Chem. Rev.* **2019**, *398*, No. 113011, DOI: 10.1016/j.ccr.2019.07.008.
- (26) Meier-Menches, S. M.; Gerner, C.; Berger, W.; Hartinger, C. G.; Keppler, B. K. Structure–activity relationships for ruthenium and osmium anticancer agents – towards clinical development. *Chem. Soc. Rev.* **2018**, *47* (3), 909–928.
- (27) Steel, T. R.; Walsh, F.; Wiczorek-Blauz, A.; Hanif, M.; Hartinger, C. G. Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. *Coord. Chem. Rev.* **2021**, *439*, No. 213890.
- (28) Tremlett, W. D. J.; Goodman, D. M.; Steel, T. R.; Kumar, S.; Wiczorek-Blauz, A.; Walsh, F. P.; Sullivan, M. P.; Hanif, M.; Hartinger, C. G. Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. *Coord. Chem. Rev.* **2021**, *445*, No. 213950.
- (29) Hanif, M.; Babak, M. V.; Hartinger, C. G. Development of anticancer agents: wizardry with osmium. *Drug Discovery Today* **2014**, *19* (10), 1640–1648.
- (30) Geldmacher, Y.; Oleszak, M.; Sheldrick, W. S. Rhodium(III) and iridium(III) complexes as anticancer agents. *Inorg. Chim. Acta* **2012**, *393*, 84–102.
- (31) Pettinari, R.; Marchetti, F.; Condello, F.; Pettinari, C.; Lupidi, G.; Scopelliti, R.; Mukhopadhyay, S.; Riedel, T.; Dyson, P. J. Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity. *Organometallics* **2014**, *33* (14), 3709–3715.
- (32) Pettinari, R.; Marchetti, F.; Pettinari, C.; Condello, F.; Pettrini, A.; Scopelliti, R.; Riedel, T.; Dyson, P. J. Organometallic rhodium(III) and iridium(III) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands. *Dalton Trans.* **2015**, *44* (47), 20523–20531.
- (33) Płażuk, D.; Wiczorek, A.; Ciszewski, W. M.; Kowalczyk, K.; Blauz, A.; Pawlędzio, S.; Makal, A.; Eurtivong, C.; Arabshahi, H. J.; Reynisson, J.; et al. Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives. *ChemMedChem* **2017**, *12* (22), 1882–1892.
- (34) Płażuk, D.; Wiczorek, A.; Blauz, A.; Rychlik, B. Synthesis and biological activities of ferrocenyl derivatives of paclitaxel. *MedChemComm* **2012**, *3* (4), 498–501.
- (35) Nicolaus, N.; Zapke, J.; Riesterer, P.; Neudörfl, J.-M.; Prokop, A.; Oschkinat, H.; Schmalz, H.-G. Azides Derived from Colchicine and their Use in Library Synthesis: a Practical Entry to New Bioactive Derivatives of an Old Natural Drug. *ChemMedChem* **2010**, *5* (5), 661–665.

- (36) Wardle, N. J.; Kalber, T.; Bell, J. D.; Bligh, S. W. A. Synthesis and characterisation of a novel tubulin-directed DO3A–colchicine conjugate with potential theranostic features. *Bioorg. Med. Chem. Lett.* **2011**, *21* (11), 3346–3348.
- (37) Kowalczyk, K.; Błaż, A.; Ciszewski, W. M.; Wieczorek, A.; Rychlik, B.; Plazuk, D. Colchicine metalocenyl bioconjugates showing high antiproliferative activities against cancer cell lines. *Dalton Trans.* **2017**, *46* (48), 17041–17052.
- (38) Ang, W. H.; De Luca, A.; Chapuis-Bernasconi, C.; Juillerat-Jeanneret, L.; Lo Bello, M.; Dyson, P. J. Organometallic ruthenium inhibitors of glutathione-S-transferase P1–1 as anticancer drugs. *ChemMedChem* **2007**, *2* (12), 1799–1806.
- (39) Ang, W. H.; Parker, L. J.; De Luca, A.; Juillerat-Jeanneret, L.; Morton, C. J.; Lo Bello, M.; Parker, M. W.; Dyson, P. J. Rational design of an organometallic glutathione transferase inhibitor. *Angew. Chem., Int. Ed.* **2009**, *48* (21), 3854–3857.
- (40) Schmid, W. F.; John, R. O.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. *Organometallics* **2007**, *26* (26), 6643–6652.
- (41) Beupérin, M.; Polat, D.; Roudesly, F.; Top, S.; Vessières, A.; Oble, J.; Jaouen, G.; Poli, G. Approach to ferrocenyl-podophyllotoxin analogs and their evaluation as anti-tumor agents. *J. Organomet. Chem.* **2017**, *839*, 83–90.
- (42) Wieczorek, A.; Błaż, A.; Makal, A.; Rychlik, B.; Plazuk, D. Synthesis and evaluation of biological properties of ferrocenyl-podophyllotoxin conjugates. *Dalton Trans.* **2017**, *46* (33), 10847–10858.
- (43) Kowalczyk, K.; Błaż, A.; Moscoh Ayine-Tora, D.; Hartinger, C. G.; Rychlik, B.; Plazuk, D. Design, Synthesis, and Evaluation of Biological Activity of Ferrocene-Ispinesib Hybrids: Impact of a Ferrocenyl Group on the Antiproliferative and Kinesin Spindle Protein Inhibitory Activity. *Chem. - Eur. J.* **2023**, *29* (49), No. e202300813.
- (44) Łomzik, M.; Hanif, M.; Budniok, A.; Błaż, A.; Makal, A.; Tchoń, D. M.; Leśniewska, B.; Tong, K. K. H.; Movassaghi, S.; Söhnel, T.; et al. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands. *Inorg. Chem.* **2020**, *59* (20), 14879–14890.
- (45) Łomzik, M.; Błaż, A.; Głodek, M.; Makal, A.; Tchoń, D.; Ayine-Tora, D. M.; Hartinger, C.; Rychlik, B.; Plazuk, D. Organometallic Ru, Os, Rh and Ir half-sandwich conjugates of ispinesib – impact of the organometallic group on the antimetabolic activity. *Dalton Trans.* **2023**, *52* (34), 11859–11874.
- (46) Chow, M. J.; Licona, C.; Pastorin, G.; Mellitzer, G.; Ang, W. H.; Gaidon, C. Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance. *Chem. Sci.* **2016**, *7* (7), 4117–4124.
- (47) Gichumbi, J. M.; Friedrich, H. B.; Omondi, B. Synthesis and characterization of piano-stool ruthenium complexes with N,N'-pyridine imine bidentate ligands and their application in styrene oxidation. *J. Organomet. Chem.* **2016**, *808*, 87–96.
- (48) Gichumbi, J. M.; Friedrich, H. B.; Omondi, B. Synthesis and characterization of half-sandwich ruthenium(II) complexes with N-alkyl pyridyl-imine ligands and their application in transfer hydrogenation of ketones. *Transit. Met. Chem.* **2016**, *41* (8), 867–877.
- (49) Burris, H. A., 3rd; Jones, S. F.; Williams, D. D.; Kathman, S. J.; Hodge, J. P.; Pandite, L.; Ho, P. T.; Boerner, S. A.; Lorusso, P. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. *Invest. New Drugs* **2011**, *29* (3), 467–472.
- (50) El Zouhairi, M.; Charabaty, A.; Pishvaian, M. J. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. *Gastrointest Cancer Res.* **2011**, *4* (1), 15–21.
- (51) Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Göschl, S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G. Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. *Chem. Commun.* **2013**, *49* (32), 3348–3350.
- (52) Kiel, W. A.; Ball, R. G.; Graham, W. A. G. Carbonyl- η -hexamethylbenzene complexes of osmium. Carbon-hydrogen activation by $(\eta$ -C₆Me₆)Os(CO)(H)₂. *J. Organomet. Chem.* **1990**, *383* (1–3), 481–496.
- (53) White, C.; Yates, A.; Maitlis, P. M.; Heinekey, D. M. (η -5-Pentamethylcyclopentadienyl)Rhodium and -Iridium Compounds. *Inorg. Synth.* **1992**, *29*, 228–234.
- (54) Holland, J. P.; Jones, M. W.; Cohrs, S.; Schibli, R.; Fischer, E. Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression. *Bioorg. Med. Chem.* **2013**, *21* (2), 496–507.
- (55) Błaż, A.; Rychlik, B. Drug-selected cell line panels for evaluation of the pharmacokinetic consequences of multidrug resistance proteins. *J. Pharmacol. Toxicol. Methods* **2017**, *84*, 57–65.